Under these regulations, Hyasynth is permitted to produce and distribute cannabinoid products to those that are also legally allowed to possess cannabinoid products. To read more on the technology that Hyasynth brings to the table
click here.
Organigram’s recent investment in Hyasynth along with some of its competitors like Cronos, Anandia, and Inmed are likely to give themselves a first-mover advantage in this space provided their research and development all pans out.
Conclusion:
Organigram’s move towards being able to produce pure THC, CBD, CBG and other minor cannabinoids at a scalable and cost-effective means could signal one of the many future paths of the cannabis space. Where other companies have built massive greenhouses or bought acres of land so that they can produce one crop of cannabis per year outdoors, purely to be sent to the extraction machine, Organigram appears to have thought of a potentially much better path.
Organigram is a top 6 producer in terms of current production, is one of the cheapest in terms of cost per gram, has global investments in Serbia and Germany and a distribution channel into Australia and has made a splash into the future of cannabinoid production and yet it trades at a fraction of the multiple of some of its peers.
27